CYP46A1 Activation by Efavirenz Leads to Behavioral Improvement without Significant Changes in Amyloid Plaque Load in the Brain of 5XFAD Mice
CYP46A1 Activation by Efavirenz Leads to Behavioral Improvement without Significant Changes in Amyloid Plaque Load in the Brain of 5XFAD Mice
A. Petrov,Morrie Lam,4 Authors,I. Pikuleva
2019 · DOI: 10.1007/s13311-019-00737-0
Neurotherapeutics · 64 Citations
TLDR
Efavirenz treatment seems to represent a model of behavioral and other improvements independent of the levels of the amyloid peptides and provides insight into potential outcomes of the future clinical trial.